Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis (Q42645688)

4 November 2017

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

4 November 2017

0 references

multiple sclerosis

0 references

author name string

C L Hirst

1

1 reference

4 November 2017

A Pace

2

1 reference

4 November 2017

T P Pickersgill

3

1 reference

4 November 2017

R Jones

4

1 reference

4 November 2017

B N McLean

5

1 reference

4 November 2017

J P Zajicek

6

1 reference

4 November 2017

N J Scolding

7

1 reference

4 November 2017

N P Robertson

8

1 reference

4 November 2017

20 February 2008

1 reference

4 November 2017

1 reference

4 November 2017

255

1 reference

4 November 2017

2

1 reference

4 November 2017

231-238

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-008-0696-y

4 November 2017

0 references

cites work

Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0696-Y

The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0696-Y

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0696-Y

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-0696-Y

Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia

21 January 2018

1 reference

12 December 2020

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

1 reference

12 December 2020

The CAMPATH-1 antigen (CDw52)

1 reference

12 December 2020

Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases

1 reference

12 December 2020

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H

1 reference

12 December 2020

Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic indicators in multiple sclerosis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

12 December 2020

Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench

1 reference

12 December 2020

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

1 reference

12 December 2020

Onset symptoms as predictors of mortality and disability in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

1 reference

12 December 2020

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Disability progression in multiple sclerosis is slower than previously reported.

1 reference

12 December 2020

Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models

1 reference

12 December 2020

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

1 reference

12 December 2020

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

1 reference

12 December 2020

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

1 reference

12 December 2020

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

1 reference

12 December 2020

Some aspects of the natural history of disseminated sclerosis

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

1 reference

12 December 2020

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

12 December 2020

Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status

1 reference

12 December 2020

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

12 December 2020

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

12 December 2020

A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

1 reference

12 December 2020

Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland

1 reference

12 December 2020

Natural history of cervical intraepithelial neoplasia: a critical review.

1 reference

12 December 2020

Reshaping human antibodies for therapy

1 reference

12 December 2020

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

12 December 2020

10.1007/S00415-008-0696-Y

Identifiers

DOI

1 reference

4 November 2017

1 reference